Alessia Bellotti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alessia Bellotti has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Ilenia Corbelli
University of Perugia
3 shared publications Paola Sarchielli
University of Perugia
3 shared publicationsAlberto Chiarugi
Careggi University Hospital - University of Florence
2 shared publicationsAlejandro Labastida-Ramirez
Division of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester; Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, University of Manchester, Manchester, UK
2 shared publicationsAlessandro Tessitore
Headache Centre of Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy
2 shared publicationsAnna Laporta
DiBraiN Department, Neurophysiopathology Unit, Bari Aldo Moro University, Bari, Italy
2 shared publications
Latest Publications
- 15 September 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (10) , 595
Long-term safety of CGRP pathway inhibitors in migraine patients with prior cerebrovascular or cardiovascular disease
- 15 September 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (10) , 595
Long-term safety of CGRP pathway inhibitors in migraine patients with prior cerebrovascular or cardiovascular disease
- Open Access
- 17 June 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (6)
CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies treatment
Aim: Calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) play a crucial role in migraine pathophysiology. In recent years, anti-CGRP(R) monoclonal antibodies (mAbs) have emerged as the first targeted and highly effective therapy for migraine. This study aimed to assess any changes in plasma CGRP levels following prophylactic treatment with anti-CGRP(R) mAbs and to compare CGRP dynamics between anti-receptor (erenumab) and anti-ligand (galcanezumab, fremanezumab) therapies. Secondary objectives were: (i) to evaluate changes in VIP and PACAP plasma levels following treatment with anti-CGRP(R) mAbs and (ii) to investigate whether baseline or post-treatment plasma levels of CGRP, VIP and PACAP were associated with clinical response to anti-CGRP(R) monoclonal antibody therapy. Methods: Between February 2022 and February 2023, we enrolled 56 migraine patients who initiated prophylaxis with either erenumab (26 patients), galcanezumab (16 patients) or fremanezumab (14 patients). Responders were defined as those achieving a ≥50% reduction in monthly migraine days after six months. Blood samples were collected at baseline and at each follow-up visit (baseline, T0; three months, T1; six months, T2; 12 months, T3). Plasma levels of CGRP, VIP and PACAP were measured using a validated radioimmunoassay and commercially available enzyme-linked immunosorbent assay kits. Results: Overall, 80.3% (45 out of 56) of patients responded to anti-CGRP(R) mAbs. No correlation was found between baseline CGRP, VIP and PACAP plasma levels and clinical response to anti-CGRP(R) mAbs therapy. Regarding CGRP trend, significant differences were found between patients treated with the anti-receptor monoclonal antibody (erenumab) and those receiving anti-ligand therapies. In patients treated with erenumab, CGRP levels did not show a significant change over the treatment period (T1–T3), whereas, in the galcanezumab group, CGRP levels significantly decreased as early as T1 ( p < 0.01). CGRP longitudinal assessment of the fremanezumab group were excluded due to assay interference with the drug. VIP and PACAP plasma levels remained stable over time for all treatments, with no significant differences between responders and non-responders. Conclusions: Galcanezumab reduced CGRP plasmatic levels already after three months, whereas erenumab did not affect significantly CGRP plasmatic levels. VIP and PACAP levels were not influenced by the therapy.
- 17 June 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (6)
Open AccessCGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies treatment
Aim: Calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) play a crucial role in migraine pathophysiology. In recent years, anti-CGRP(R) monoclonal antibodies (mAbs) have emerged as the first targeted and highly effective therapy for migraine. This study aimed to assess any changes in plasma CGRP levels following prophylactic treatment with anti-CGRP(R) mAbs and to compare CGRP dynamics between anti-receptor (erenumab) and anti-ligand (galcanezumab, fremanezumab) therapies. Secondary objectives were: (i) to evaluate changes in VIP and PACAP plasma levels following treatment with anti-CGRP(R) mAbs and (ii) to investigate whether baseline or post-treatment plasma levels of CGRP, VIP and PACAP were associated with clinical response to anti-CGRP(R) monoclonal antibody therapy. Methods: Between February 2022 and February 2023, we enrolled 56 migraine patients who initiated prophylaxis with either erenumab (26 patients), galcanezumab (16 patients) or fremanezumab (14 patients). Responders were defined as those achieving a ≥50% reduction in monthly migraine days after six months. Blood samples were collected at baseline and at each follow-up visit (baseline, T0; three months, T1; six months, T2; 12 months, T3). Plasma levels of CGRP, VIP and PACAP were measured using a validated radioimmunoassay and commercially available enzyme-linked immunosorbent assay kits. Results: Overall, 80.3% (45 out of 56) of patients responded to anti-CGRP(R) mAbs. No correlation was found between baseline CGRP, VIP and PACAP plasma levels and clinical response to anti-CGRP(R) mAbs therapy. Regarding CGRP trend, significant differences were found between patients treated with the anti-receptor monoclonal antibody (erenumab) and those receiving anti-ligand therapies. In patients treated with erenumab, CGRP levels did not show a significant change over the treatment period (T1–T3), whereas, in the galcanezumab group, CGRP levels significantly decreased as early as T1 ( p < 0.01). CGRP longitudinal assessment of the fremanezumab group were excluded due to assay interference with the drug. VIP and PACAP plasma levels remained stable over time for all treatments, with no significant differences between responders and non-responders. Conclusions: Galcanezumab reduced CGRP plasmatic levels already after three months, whereas erenumab did not affect significantly CGRP plasmatic levels. VIP and PACAP levels were not influenced by the therapy.
- Top Cited PapersOpen Access
- 25 April 2025
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (4)
Evidence-based guidelines for the pharmacological treatment of migraine
We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the Grading of Recommendations, Assessment, Development and Evaluation approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.
- 25 April 2025
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (4)
Top Cited PapersOpen AccessEvidence-based guidelines for the pharmacological treatment of migraine
We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the Grading of Recommendations, Assessment, Development and Evaluation approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.
- Top Cited PapersOpen Access
- 25 April 2025
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (4)
Evidence-based guidelines for the pharmacological treatment of migraine, summary version
We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the GRADE approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.
- 25 April 2025
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (4)
Top Cited PapersOpen AccessEvidence-based guidelines for the pharmacological treatment of migraine, summary version
We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the GRADE approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.
- Open Access
- 29 January 2025
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 8
Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study
Background and Aim: Eptinezumab is a quarterly intravenous infusion monoclonal antibody (mAb) with high affinity for calcitonin gene related peptide (CGRP) and a long-lasting mechanism of action. In our retrospective observational study, we sought to investigate the effectiveness and safety of eptinezumab both in mAbs-naïve and mAbs-non responders’ patients. Methods: We collected clinical data from electronic charts of 30 migraineurs who underwent six months of eptinezumab treatment; 18 patients had never undergone mAbs-prophylaxis (G1) while 12 had been non-responders to erenumab/galcanezumab (G2). Monthly Headache Days (MHDs), MIDAS, HIT6 and ASC scores were recorded before eptinezumab (T0) and thereafter every three months. Patients were considered responders whenever MHDs reduction was >50% at six months (T2). Results: Overall, 25 out of 30 patients (15 in G1 and 10 in G2) were eptinezumab responders (83.3%). Headache frequency (MHDs) at T0 was 12.4 in G1 and 17.0 in G2, while at T2 it was 7.1 in G1 and 8.0 in G2 (p-value < 0.0001). Significant reductions in MIDAS, HIT6 and ASC scores were also observed. No safety concerns were registered. Conclusions: Based upon our retrospective observational study, eptinezumab might be effective and safe also for those migraineurs who resulted being non-responders to other anti-CGRP(R) mAbs.
- 29 January 2025
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 8
Open AccessEffectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study
Background and Aim: Eptinezumab is a quarterly intravenous infusion monoclonal antibody (mAb) with high affinity for calcitonin gene related peptide (CGRP) and a long-lasting mechanism of action. In our retrospective observational study, we sought to investigate the effectiveness and safety of eptinezumab both in mAbs-naïve and mAbs-non responders’ patients. Methods: We collected clinical data from electronic charts of 30 migraineurs who underwent six months of eptinezumab treatment; 18 patients had never undergone mAbs-prophylaxis (G1) while 12 had been non-responders to erenumab/galcanezumab (G2). Monthly Headache Days (MHDs), MIDAS, HIT6 and ASC scores were recorded before eptinezumab (T0) and thereafter every three months. Patients were considered responders whenever MHDs reduction was >50% at six months (T2). Results: Overall, 25 out of 30 patients (15 in G1 and 10 in G2) were eptinezumab responders (83.3%). Headache frequency (MHDs) at T0 was 12.4 in G1 and 17.0 in G2, while at T2 it was 7.1 in G1 and 8.0 in G2 (p-value < 0.0001). Significant reductions in MIDAS, HIT6 and ASC scores were also observed. No safety concerns were registered. Conclusions: Based upon our retrospective observational study, eptinezumab might be effective and safe also for those migraineurs who resulted being non-responders to other anti-CGRP(R) mAbs.